What would you like to look for?
Site search
Search filters

Rigeto Investors acquired prevention-center

28 April 2023

A group of investors advised by Munich-based Rigeto Unternehmerkapital GmbH ("Rigeto") has acquired prevention-center as an add-on to the Matignon Group.

CITIC becomes largest shareholder in MedAlliance

22 March 2021

Trustar Capital (formerly known as CITIC Capital Partners), a private equity affiliate of CITIC Capital Holdings Limited, has completed its over USD 50.0m investment in the Switzerland based global leading medical technology company MedAlliance SA ("MedAlliance"), becoming MedAlliance's single largest shareholder.

Oviva raises USD 21M to roll out digital diabetes treatment in Europe

11 February 2020

Oviva raises USD 21M to roll out digital diabetes treatment in Europe.

The round was led by Swiss healthtech investor MTIP, joined by Earlybird as new investors. Existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures...

Anaveon closes CHF 35 m Series A financing

28 February 2019
22 February 2019

Anaveon, an immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the Novartis Venture Fund. The company was founded with financing from BaseLaunch,...

Oculis in-licenses novel phase II-stage Anti-TNF alpha antibody fragment

9 January 2019
19 February 2019

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has entered into an agreement to in license a novel topical anti-TNF alpha antibody from Novartis. The...

Biovotion extends Series A Financing Round

12 December 2016

VISCHER assists Harmony Medical Inc. as investor in the second closing of the ongoing CHF 10 m Series A financing round of Biovotion Ltd., Zürich. Biovotion Ltd is a leading wearable physiology monitoring company and provides...

Celgene acquires EngMab

19 October 2016

Celgene (NASDAQ: CELG) has bought Swiss biotech EngMab for USD 600 million. EngMab's focus is on T-cell bispecific antibodies (TCBs). TCBs bind simultaneously to a target on a tumor cell and to the T-cell receptor complex, leading...

Decision of the Swiss Federal Administrative Court (Bundesverwaltungsgericht) Concerning the Rates of University Hospitals

6 May 2015

The Swiss Federal Administrative Court (Bundesverwaltungsgericht) decided on important issues concerning the calculation of payment rates of university hospitals. VISCHER (Andreas Albrecht and Michael Waldner) represented the...

Sale and lease-back of kneipp-hof's operating real estate

25 September 2014

Credit Suisse Real Estate Fund LivingPlus (CS REF LivingPlus) acquires all operating real estate from kneipp-hof Dussnang which leases the operating real estate back. The VISCHER Team, led by Benedict F. Christ (partner...

Vamed acquires kneipp-hof Dussnang AG

25 September 2014

The international health care Provider VAMED (part of the German Fresenius group) extends its Swiss activities and acquires 100 percent of kneipp-hof Dussnang AG. This allows the seller, Kloster Heiligkreuz of Cham, to implement a...

You are currently offline. Some pages or content may fail to load.